Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
06:00am, Monday, 16'th Mar 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two peer-reviewed publications highlighting the clinical utility o
Natera, Inc. $NTRA Position Reduced by Bank of Hawaii
03:07am, Saturday, 14'th Mar 2026
Bank of Hawaii reduced its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 18.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Com
Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
12:49pm, Thursday, 12'th Mar 2026
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis
08:00am, Thursday, 12'th Mar 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the commercial launch of Zenith genomics, its next-generation whol
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
08:00am, Thursday, 12'th Mar 2026
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
01:52am, Thursday, 12'th Mar 2026
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Focus Partners Advisor Solutions LLC Has $1.70 Million Stake in Natera, Inc. $NTRA
04:00am, Friday, 06'th Mar 2026
Focus Partners Advisor Solutions LLC grew its stake in Natera, Inc. (NASDAQ: NTRA) by 72.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (S
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
01:52am, Thursday, 05'th Mar 2026
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:42pm, Wednesday, 04'th Mar 2026
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
10:05am, Friday, 27'th Feb 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the Amer
Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of “Moderate Buy” from Analysts
01:58am, Friday, 27'th Feb 2026
Natera, Inc. (NASDAQ: NTRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eighteen analysts that are presently covering the firm, MarketBeat.com reports. One rese
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
09:37pm, Thursday, 26'th Feb 2026
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates
07:46pm, Thursday, 26'th Feb 2026
Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago.
Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
07:30pm, Thursday, 26'th Feb 2026
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors
07:05pm, Thursday, 26'th Feb 2026
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetiz
